| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 67 | 2023 | 865 | 8.260 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 26 | 2024 | 235 | 6.510 |
Why?
|
| Polycystic Kidney Diseases | 15 | 2025 | 71 | 6.460 |
Why?
|
| Kidney | 49 | 2025 | 1495 | 5.400 |
Why?
|
| Cisplatin | 14 | 2020 | 334 | 4.220 |
Why?
|
| Autophagy | 14 | 2024 | 286 | 3.210 |
Why?
|
| TOR Serine-Threonine Kinases | 12 | 2025 | 449 | 3.090 |
Why?
|
| Interleukin-18 | 22 | 2019 | 235 | 2.860 |
Why?
|
| TRPP Cation Channels | 12 | 2024 | 74 | 2.690 |
Why?
|
| Kidney Tubules, Proximal | 22 | 2015 | 130 | 2.630 |
Why?
|
| Sirolimus | 8 | 2019 | 281 | 2.180 |
Why?
|
| Caspase 1 | 17 | 2019 | 148 | 2.170 |
Why?
|
| Disease Models, Animal | 26 | 2025 | 4557 | 2.040 |
Why?
|
| Kidney Tubules | 16 | 2019 | 117 | 2.030 |
Why?
|
| Apoptosis | 32 | 2020 | 2430 | 2.000 |
Why?
|
| Caspases | 16 | 2019 | 232 | 1.820 |
Why?
|
| Calpain | 18 | 2006 | 61 | 1.710 |
Why?
|
| Kidney Diseases | 9 | 2022 | 427 | 1.600 |
Why?
|
| Kidney Tubular Necrosis, Acute | 6 | 2015 | 26 | 1.450 |
Why?
|
| Animals | 112 | 2025 | 38058 | 1.440 |
Why?
|
| Cell Proliferation | 11 | 2024 | 2496 | 1.440 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 2194 | 1.430 |
Why?
|
| Mice, Inbred C57BL | 37 | 2025 | 5992 | 1.400 |
Why?
|
| Caspase Inhibitors | 12 | 2019 | 81 | 1.310 |
Why?
|
| Caspase 3 | 19 | 2016 | 238 | 1.290 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2020 | 969 | 1.220 |
Why?
|
| Cysts | 4 | 2024 | 111 | 1.160 |
Why?
|
| Mice | 54 | 2025 | 18339 | 1.110 |
Why?
|
| Biomarkers | 33 | 2023 | 4271 | 1.110 |
Why?
|
| Acute-Phase Proteins | 14 | 2019 | 67 | 1.100 |
Why?
|
| Lipocalins | 13 | 2019 | 35 | 1.090 |
Why?
|
| Ischemia | 11 | 2019 | 421 | 1.090 |
Why?
|
| Reperfusion Injury | 7 | 2011 | 300 | 0.950 |
Why?
|
| Nephrectomy | 5 | 2021 | 158 | 0.950 |
Why?
|
| Immunosuppressive Agents | 7 | 2018 | 846 | 0.910 |
Why?
|
| Rats | 28 | 2024 | 5597 | 0.900 |
Why?
|
| Cytokines | 10 | 2024 | 2061 | 0.870 |
Why?
|
| Lymphoid Tissue | 1 | 2025 | 80 | 0.870 |
Why?
|
| Autophagy-Related Proteins | 3 | 2021 | 46 | 0.870 |
Why?
|
| Urate Oxidase | 1 | 2024 | 13 | 0.840 |
Why?
|
| Deoxyglucose | 1 | 2024 | 51 | 0.840 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2014 | 116 | 0.830 |
Why?
|
| Hypertension | 8 | 2022 | 1263 | 0.820 |
Why?
|
| Hibernation | 3 | 2016 | 80 | 0.810 |
Why?
|
| Lipocalin-2 | 15 | 2020 | 79 | 0.780 |
Why?
|
| Necrosis | 6 | 2014 | 244 | 0.780 |
Why?
|
| Interleukin-1beta | 5 | 2019 | 395 | 0.780 |
Why?
|
| Male | 93 | 2025 | 72315 | 0.770 |
Why?
|
| Uric Acid | 1 | 2024 | 166 | 0.760 |
Why?
|
| Interleukin-33 | 4 | 2017 | 45 | 0.740 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2022 | 25 | 0.740 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 168 | 0.730 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 76 | 0.700 |
Why?
|
| Blood Urea Nitrogen | 8 | 2020 | 53 | 0.690 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2013 | 623 | 0.680 |
Why?
|
| Cysteine Proteinase Inhibitors | 7 | 2008 | 50 | 0.670 |
Why?
|
| Kidney Transplantation | 8 | 2018 | 704 | 0.660 |
Why?
|
| Lovastatin | 2 | 2013 | 37 | 0.650 |
Why?
|
| Piperidines | 1 | 2022 | 217 | 0.650 |
Why?
|
| Trehalose | 1 | 2020 | 35 | 0.640 |
Why?
|
| Amino Acid Chloromethyl Ketones | 5 | 2014 | 24 | 0.630 |
Why?
|
| Chemokine CX3CL1 | 3 | 2011 | 25 | 0.620 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2020 | 128 | 0.620 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 427 | 0.620 |
Why?
|
| Metformin | 1 | 2023 | 318 | 0.610 |
Why?
|
| Adenine | 1 | 2022 | 339 | 0.610 |
Why?
|
| Apolipoproteins | 6 | 2017 | 38 | 0.610 |
Why?
|
| Naphthyridines | 1 | 2019 | 20 | 0.590 |
Why?
|
| Cardiac Surgical Procedures | 10 | 2017 | 609 | 0.590 |
Why?
|
| Interleukin-6 | 9 | 2019 | 780 | 0.590 |
Why?
|
| Organ Preservation | 4 | 2015 | 130 | 0.590 |
Why?
|
| Protein Kinase C | 1 | 2020 | 252 | 0.590 |
Why?
|
| Cardiomegaly | 1 | 2020 | 174 | 0.580 |
Why?
|
| Cell Cycle Proteins | 2 | 2019 | 628 | 0.570 |
Why?
|
| Mice, Knockout | 14 | 2025 | 3121 | 0.570 |
Why?
|
| Chemokine CXCL1 | 6 | 2015 | 76 | 0.560 |
Why?
|
| Endothelial Cells | 5 | 2022 | 869 | 0.550 |
Why?
|
| Humans | 99 | 2024 | 144759 | 0.540 |
Why?
|
| Cold Ischemia | 3 | 2015 | 40 | 0.540 |
Why?
|
| Mice, Mutant Strains | 7 | 2019 | 299 | 0.530 |
Why?
|
| Interleukin-1alpha | 2 | 2014 | 57 | 0.520 |
Why?
|
| Inflammation Mediators | 5 | 2021 | 509 | 0.510 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2024 | 2527 | 0.500 |
Why?
|
| Creatinine | 12 | 2015 | 506 | 0.500 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2015 | 1129 | 0.490 |
Why?
|
| Macrophages | 5 | 2013 | 1511 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 257 | 0.490 |
Why?
|
| Quinolines | 3 | 2014 | 193 | 0.480 |
Why?
|
| Lipoprotein(a) | 6 | 2001 | 68 | 0.480 |
Why?
|
| Interleukins | 3 | 2014 | 248 | 0.480 |
Why?
|
| Epithelial Cells | 5 | 2019 | 1125 | 0.480 |
Why?
|
| Renin-Angiotensin System | 3 | 2013 | 78 | 0.470 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2008 | 221 | 0.470 |
Why?
|
| Hypoxia | 12 | 2000 | 1199 | 0.470 |
Why?
|
| Phenylenediamines | 1 | 2015 | 12 | 0.470 |
Why?
|
| Mutation | 2 | 2019 | 4089 | 0.460 |
Why?
|
| Cystatin C | 6 | 2019 | 65 | 0.460 |
Why?
|
| Genetic Therapy | 2 | 2014 | 313 | 0.460 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2013 | 439 | 0.450 |
Why?
|
| Carrier Proteins | 4 | 2014 | 737 | 0.450 |
Why?
|
| Angiotensinogen | 1 | 2014 | 4 | 0.440 |
Why?
|
| Neutrophil Infiltration | 4 | 2013 | 104 | 0.440 |
Why?
|
| Sciuridae | 2 | 2016 | 152 | 0.420 |
Why?
|
| Phenanthrenes | 1 | 2014 | 12 | 0.420 |
Why?
|
| Interleukin-8 | 2 | 2013 | 271 | 0.420 |
Why?
|
| Diterpenes | 1 | 2014 | 26 | 0.420 |
Why?
|
| Lung Injury | 2 | 2015 | 237 | 0.420 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2011 | 297 | 0.410 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 383 | 0.400 |
Why?
|
| Purines | 1 | 2014 | 187 | 0.390 |
Why?
|
| Enalapril | 4 | 2007 | 16 | 0.390 |
Why?
|
| Kidney Function Tests | 5 | 2015 | 157 | 0.380 |
Why?
|
| Lymphocyte Depletion | 3 | 2015 | 132 | 0.380 |
Why?
|
| Tumor Burden | 3 | 2020 | 319 | 0.370 |
Why?
|
| Cysteine Endopeptidases | 6 | 2006 | 73 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 5 | 2015 | 598 | 0.370 |
Why?
|
| Oxidative Stress | 3 | 2019 | 1339 | 0.370 |
Why?
|
| Proteinuria | 4 | 2022 | 102 | 0.360 |
Why?
|
| Calcium | 9 | 2000 | 1183 | 0.360 |
Why?
|
| Signal Transduction | 9 | 2021 | 5226 | 0.360 |
Why?
|
| NF-kappa B | 1 | 2015 | 661 | 0.350 |
Why?
|
| Cells, Cultured | 10 | 2019 | 4154 | 0.350 |
Why?
|
| Reperfusion | 1 | 2011 | 54 | 0.350 |
Why?
|
| Enzyme Inhibitors | 4 | 2024 | 824 | 0.350 |
Why?
|
| Immunoblotting | 6 | 2014 | 300 | 0.350 |
Why?
|
| Diuretics | 3 | 2007 | 68 | 0.340 |
Why?
|
| Peroxidase | 5 | 2015 | 168 | 0.340 |
Why?
|
| Phosphorylation | 5 | 2019 | 1732 | 0.340 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 3 | 2021 | 139 | 0.330 |
Why?
|
| Endotoxemia | 4 | 2005 | 87 | 0.330 |
Why?
|
| Glomerular Filtration Rate | 8 | 2024 | 760 | 0.330 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2015 | 1217 | 0.320 |
Why?
|
| Indoles | 1 | 2014 | 501 | 0.320 |
Why?
|
| Liver Diseases | 2 | 2011 | 304 | 0.320 |
Why?
|
| Female | 46 | 2024 | 78271 | 0.320 |
Why?
|
| Neutrophils | 5 | 2007 | 1134 | 0.310 |
Why?
|
| Kringles | 3 | 1999 | 5 | 0.310 |
Why?
|
| Delayed Graft Function | 3 | 2014 | 46 | 0.310 |
Why?
|
| Renal Replacement Therapy | 3 | 2012 | 100 | 0.310 |
Why?
|
| Postoperative Complications | 10 | 2017 | 2919 | 0.310 |
Why?
|
| Interleukin-1 | 5 | 2015 | 961 | 0.310 |
Why?
|
| Adaptation, Physiological | 2 | 2013 | 570 | 0.310 |
Why?
|
| Protein Kinases | 2 | 2008 | 315 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2019 | 436 | 0.290 |
Why?
|
| Disease Progression | 9 | 2014 | 2847 | 0.290 |
Why?
|
| L-Lactate Dehydrogenase | 9 | 2007 | 115 | 0.290 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2008 | 7 | 0.290 |
Why?
|
| Drug Design | 1 | 2010 | 173 | 0.290 |
Why?
|
| Drug Delivery Systems | 2 | 2010 | 380 | 0.290 |
Why?
|
| Macrophages, Peritoneal | 1 | 2009 | 89 | 0.280 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2008 | 6 | 0.280 |
Why?
|
| Complement Factor B | 3 | 2023 | 106 | 0.280 |
Why?
|
| Dendritic Cells | 1 | 2012 | 499 | 0.280 |
Why?
|
| CD11b Antigen | 4 | 2009 | 60 | 0.270 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 2 | 2021 | 63 | 0.270 |
Why?
|
| Receptors, Chemokine | 1 | 2007 | 47 | 0.270 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 2637 | 0.270 |
Why?
|
| Liver Transplantation | 2 | 2013 | 823 | 0.270 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2021 | 173 | 0.270 |
Why?
|
| Nephrosis, Lipoid | 1 | 2007 | 11 | 0.270 |
Why?
|
| Nephrology | 1 | 2008 | 60 | 0.270 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 130 | 0.260 |
Why?
|
| Nitric Oxide Synthase | 9 | 2001 | 235 | 0.260 |
Why?
|
| Ionomycin | 4 | 2000 | 22 | 0.260 |
Why?
|
| Blotting, Western | 8 | 2012 | 1187 | 0.260 |
Why?
|
| Apolipoproteins A | 4 | 2001 | 18 | 0.260 |
Why?
|
| Nitric Oxide | 13 | 2007 | 897 | 0.260 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 109 | 0.260 |
Why?
|
| Pyrimidinones | 2 | 2020 | 126 | 0.260 |
Why?
|
| Gene Deletion | 2 | 2008 | 389 | 0.250 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 381 | 0.250 |
Why?
|
| Critical Illness | 6 | 2023 | 891 | 0.250 |
Why?
|
| Peptide Hydrolases | 3 | 2009 | 105 | 0.250 |
Why?
|
| Biological Assay | 3 | 2021 | 128 | 0.240 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2019 | 79 | 0.230 |
Why?
|
| Cell Line | 7 | 2021 | 2882 | 0.230 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2025 | 13 | 0.230 |
Why?
|
| Prospective Studies | 19 | 2023 | 7990 | 0.230 |
Why?
|
| Regulatory-Associated Protein of mTOR | 1 | 2025 | 24 | 0.230 |
Why?
|
| Rewarming | 2 | 2016 | 21 | 0.230 |
Why?
|
| MAP Kinase Signaling System | 2 | 2020 | 310 | 0.230 |
Why?
|
| Cell Membrane | 2 | 2007 | 706 | 0.220 |
Why?
|
| Cold Temperature | 4 | 2016 | 209 | 0.220 |
Why?
|
| Albuminuria | 3 | 2019 | 190 | 0.220 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2019 | 169 | 0.220 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2022 | 124 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 2027 | 0.220 |
Why?
|
| Blood Pressure | 8 | 2022 | 1769 | 0.220 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2015 | 266 | 0.220 |
Why?
|
| Oxypurinol | 1 | 2024 | 3 | 0.210 |
Why?
|
| Kidney Cortex | 3 | 2004 | 27 | 0.210 |
Why?
|
| Oxonic Acid | 1 | 2024 | 13 | 0.210 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 2925 | 0.210 |
Why?
|
| Neoplasms | 2 | 2019 | 2875 | 0.210 |
Why?
|
| Xanthine Oxidase | 1 | 2024 | 79 | 0.210 |
Why?
|
| Chemokines | 3 | 2010 | 218 | 0.210 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2006 | 221 | 0.200 |
Why?
|
| Organ Size | 3 | 2010 | 463 | 0.200 |
Why?
|
| Lysosomes | 2 | 2021 | 128 | 0.200 |
Why?
|
| Phospholipases A | 6 | 2001 | 98 | 0.200 |
Why?
|
| Lactates | 1 | 2023 | 83 | 0.200 |
Why?
|
| Renal Circulation | 5 | 2013 | 75 | 0.200 |
Why?
|
| Ionophores | 2 | 2000 | 21 | 0.200 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 3 | 2019 | 41 | 0.190 |
Why?
|
| Leukocyte Elastase | 3 | 1999 | 75 | 0.190 |
Why?
|
| Metalloendopeptidases | 2 | 2001 | 62 | 0.190 |
Why?
|
| Predictive Value of Tests | 8 | 2016 | 2115 | 0.190 |
Why?
|
| Middle Aged | 26 | 2018 | 35875 | 0.190 |
Why?
|
| Adult | 26 | 2024 | 40449 | 0.190 |
Why?
|
| Hospitalization | 1 | 2013 | 2433 | 0.190 |
Why?
|
| Apolipoproteins B | 2 | 2001 | 47 | 0.190 |
Why?
|
| Inflammasomes | 1 | 2024 | 146 | 0.190 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 459 | 0.190 |
Why?
|
| Time Factors | 9 | 2017 | 7173 | 0.180 |
Why?
|
| RNA, Messenger | 6 | 2014 | 2832 | 0.180 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2011 | 370 | 0.180 |
Why?
|
| Lipoproteins, HDL | 3 | 2017 | 101 | 0.180 |
Why?
|
| Kidney Glomerulus | 3 | 2011 | 128 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 74 | 0.180 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2023 | 190 | 0.180 |
Why?
|
| Cathepsin B | 3 | 2005 | 16 | 0.180 |
Why?
|
| Body Temperature | 2 | 2013 | 229 | 0.170 |
Why?
|
| Peptide Fragments | 4 | 2000 | 699 | 0.170 |
Why?
|
| Multiprotein Complexes | 2 | 2014 | 172 | 0.170 |
Why?
|
| Oxidants | 1 | 2001 | 103 | 0.170 |
Why?
|
| Mice, Transgenic | 5 | 2012 | 2182 | 0.170 |
Why?
|
| Autophagy-Related Protein 12 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2020 | 8 | 0.160 |
Why?
|
| Caspase 8 | 3 | 2005 | 47 | 0.160 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2015 | 153 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 240 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2022 | 8265 | 0.160 |
Why?
|
| Cathepsins | 3 | 1996 | 24 | 0.160 |
Why?
|
| Prognosis | 9 | 2016 | 4282 | 0.160 |
Why?
|
| Butadienes | 1 | 2020 | 37 | 0.160 |
Why?
|
| Chloroquine | 1 | 2020 | 53 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2013 | 851 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2017 | 3604 | 0.160 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2019 | 24 | 0.150 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2005 | 121 | 0.150 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2020 | 76 | 0.150 |
Why?
|
| Hospital Mortality | 3 | 2016 | 1030 | 0.150 |
Why?
|
| Body Weight | 3 | 2010 | 976 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 63 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 557 | 0.150 |
Why?
|
| Models, Animal | 2 | 2011 | 392 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2019 | 24 | 0.150 |
Why?
|
| Trefoil Factor-3 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2001 | 477 | 0.150 |
Why?
|
| Netrin-1 | 1 | 2019 | 15 | 0.150 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 2 | 2010 | 10 | 0.150 |
Why?
|
| Clusterin | 1 | 2019 | 11 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2019 | 14 | 0.150 |
Why?
|
| beta 2-Microglobulin | 1 | 2019 | 47 | 0.150 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2016 | 47 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2000 | 219 | 0.150 |
Why?
|
| ErbB Receptors | 1 | 2022 | 627 | 0.140 |
Why?
|
| Early Diagnosis | 4 | 2013 | 249 | 0.140 |
Why?
|
| Heart Failure, Diastolic | 1 | 2019 | 24 | 0.140 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2019 | 18 | 0.140 |
Why?
|
| Membrane Glycoproteins | 3 | 2013 | 496 | 0.140 |
Why?
|
| Nitriles | 1 | 2020 | 205 | 0.140 |
Why?
|
| Proteins | 3 | 2013 | 1021 | 0.140 |
Why?
|
| Acute Lung Injury | 2 | 2012 | 303 | 0.140 |
Why?
|
| Inflammation | 1 | 2010 | 2878 | 0.140 |
Why?
|
| Pyridones | 1 | 2020 | 199 | 0.140 |
Why?
|
| Glycine | 3 | 1997 | 187 | 0.140 |
Why?
|
| Metabolomics | 2 | 2021 | 727 | 0.140 |
Why?
|
| Oncogene Proteins | 2 | 2015 | 61 | 0.140 |
Why?
|
| Exosomes | 1 | 2019 | 104 | 0.130 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2011 | 186 | 0.130 |
Why?
|
| In Vitro Techniques | 6 | 2000 | 1047 | 0.130 |
Why?
|
| Flow Cytometry | 3 | 2011 | 1173 | 0.130 |
Why?
|
| Renal Dialysis | 3 | 2011 | 462 | 0.130 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2017 | 3 | 0.130 |
Why?
|
| bcl-X Protein | 2 | 2011 | 45 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
|
| Urinalysis | 1 | 2017 | 80 | 0.130 |
Why?
|
| Endopeptidases | 2 | 1995 | 82 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2024 | 1886 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 442 | 0.130 |
Why?
|
| Chlorophyta | 2 | 2009 | 13 | 0.120 |
Why?
|
| Cyclosporine | 3 | 2012 | 265 | 0.120 |
Why?
|
| Perfusion | 2 | 2011 | 250 | 0.120 |
Why?
|
| Aged | 16 | 2017 | 25913 | 0.120 |
Why?
|
| T-Box Domain Proteins | 1 | 2017 | 106 | 0.120 |
Why?
|
| Glycosaminoglycans | 1 | 2016 | 74 | 0.120 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2014 | 23 | 0.120 |
Why?
|
| Stress, Physiological | 2 | 2010 | 453 | 0.120 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 14 | 0.120 |
Why?
|
| Swine | 6 | 2019 | 833 | 0.120 |
Why?
|
| Thiones | 1 | 2015 | 11 | 0.120 |
Why?
|
| Heart | 3 | 2019 | 636 | 0.120 |
Why?
|
| Antibodies | 4 | 2012 | 401 | 0.120 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2015 | 22 | 0.120 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 69 | 0.120 |
Why?
|
| Cell Hypoxia | 3 | 2007 | 247 | 0.120 |
Why?
|
| Caspase 2 | 2 | 2006 | 12 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2005 | 1716 | 0.110 |
Why?
|
| Spectrin | 3 | 2000 | 14 | 0.110 |
Why?
|
| Heterozygote | 2 | 2007 | 315 | 0.110 |
Why?
|
| Shock, Septic | 2 | 2016 | 216 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 116 | 0.110 |
Why?
|
| Homozygote | 1 | 2015 | 199 | 0.110 |
Why?
|
| Child | 9 | 2023 | 22633 | 0.110 |
Why?
|
| CD36 Antigens | 1 | 2014 | 32 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 384 | 0.110 |
Why?
|
| Survival Rate | 2 | 2011 | 2089 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
|
| Apoprotein(a) | 4 | 1999 | 8 | 0.110 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2015 | 24 | 0.110 |
Why?
|
| Furosemide | 2 | 2007 | 37 | 0.110 |
Why?
|
| Caspase 9 | 2 | 2004 | 55 | 0.110 |
Why?
|
| Substrate Specificity | 3 | 2000 | 388 | 0.110 |
Why?
|
| Protective Agents | 1 | 2014 | 42 | 0.110 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2014 | 17 | 0.110 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2014 | 27 | 0.110 |
Why?
|
| Interleukin-12 | 1 | 2014 | 117 | 0.110 |
Why?
|
| Epoxy Compounds | 1 | 2014 | 32 | 0.100 |
Why?
|
| Incidence | 2 | 2013 | 2879 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2010 | 1053 | 0.100 |
Why?
|
| Phospholipases A2 | 5 | 2001 | 79 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2012 | 1253 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 75 | 0.100 |
Why?
|
| Dogs | 1 | 2014 | 437 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 377 | 0.090 |
Why?
|
| Acute Disease | 3 | 2012 | 1030 | 0.090 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.090 |
Why?
|
| Glomerulonephritis | 1 | 1992 | 45 | 0.090 |
Why?
|
| Acrylates | 3 | 2006 | 48 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2014 | 627 | 0.090 |
Why?
|
| Risk Factors | 8 | 2017 | 10779 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 653 | 0.090 |
Why?
|
| Fibrosis | 1 | 2014 | 548 | 0.090 |
Why?
|
| Cilia | 1 | 2013 | 173 | 0.090 |
Why?
|
| Clodronic Acid | 1 | 2012 | 19 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 479 | 0.090 |
Why?
|
| Research Design | 1 | 2018 | 1135 | 0.090 |
Why?
|
| Diphtheria Toxin | 1 | 2012 | 65 | 0.090 |
Why?
|
| Amino Acid Sequence | 5 | 1999 | 2155 | 0.090 |
Why?
|
| Chemokine CCL2 | 1 | 2012 | 115 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 2608 | 0.090 |
Why?
|
| Amlodipine | 2 | 2002 | 9 | 0.090 |
Why?
|
| Heart Diseases | 2 | 2013 | 349 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1694 | 0.090 |
Why?
|
| Beclin-1 | 1 | 2011 | 11 | 0.080 |
Why?
|
| Raffinose | 1 | 2011 | 29 | 0.080 |
Why?
|
| Area Under Curve | 4 | 2013 | 330 | 0.080 |
Why?
|
| Warm Ischemia | 1 | 2011 | 18 | 0.080 |
Why?
|
| Arousal | 1 | 2011 | 157 | 0.080 |
Why?
|
| Allopurinol | 1 | 2011 | 69 | 0.080 |
Why?
|
| Sus scrofa | 1 | 2011 | 64 | 0.080 |
Why?
|
| Ribosomal Protein S6 | 1 | 2010 | 18 | 0.080 |
Why?
|
| Organ Preservation Solutions | 1 | 2011 | 47 | 0.080 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 161 | 0.080 |
Why?
|
| Nucleosides | 1 | 2010 | 25 | 0.080 |
Why?
|
| Matrix Metalloproteinase 12 | 2 | 2001 | 7 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 157 | 0.080 |
Why?
|
| Protein Kinase C-alpha | 1 | 2010 | 37 | 0.080 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2011 | 73 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2014 | 707 | 0.080 |
Why?
|
| Cell Fractionation | 2 | 2000 | 52 | 0.080 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2010 | 87 | 0.080 |
Why?
|
| Cell Movement | 2 | 2007 | 965 | 0.080 |
Why?
|
| Death | 1 | 2011 | 130 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1406 | 0.080 |
Why?
|
| Rats, Mutant Strains | 2 | 2012 | 20 | 0.080 |
Why?
|
| Coumarins | 2 | 2000 | 17 | 0.080 |
Why?
|
| Lipoproteins, LDL | 2 | 2001 | 119 | 0.080 |
Why?
|
| Protein Precursors | 3 | 1985 | 137 | 0.080 |
Why?
|
| Nucleotides | 1 | 2010 | 128 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2016 | 11679 | 0.080 |
Why?
|
| Intensive Care Units | 3 | 2017 | 916 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 196 | 0.080 |
Why?
|
| Pancreatic Elastase | 2 | 2001 | 55 | 0.070 |
Why?
|
| Adenosine | 1 | 2011 | 255 | 0.070 |
Why?
|
| Pneumonia | 2 | 2012 | 631 | 0.070 |
Why?
|
| Respiration, Artificial | 2 | 2016 | 708 | 0.070 |
Why?
|
| Glutathione | 1 | 2011 | 375 | 0.070 |
Why?
|
| Seasons | 1 | 2011 | 556 | 0.070 |
Why?
|
| DNA Fragmentation | 2 | 2009 | 39 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 178 | 0.070 |
Why?
|
| Molecular Sequence Data | 3 | 1999 | 2930 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2010 | 199 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 194 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 272 | 0.070 |
Why?
|
| Macrophages, Alveolar | 1 | 2011 | 368 | 0.070 |
Why?
|
| Adoptive Transfer | 1 | 2009 | 198 | 0.070 |
Why?
|
| Dipeptides | 2 | 2001 | 57 | 0.070 |
Why?
|
| Enzyme Activation | 3 | 2000 | 766 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 2363 | 0.070 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 965 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1489 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2008 | 277 | 0.070 |
Why?
|
| Lung Diseases | 1 | 1995 | 787 | 0.070 |
Why?
|
| Octreotide | 1 | 2008 | 23 | 0.070 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2007 | 19 | 0.070 |
Why?
|
| Benzazepines | 1 | 2008 | 35 | 0.070 |
Why?
|
| Antimycin A | 1 | 2007 | 14 | 0.070 |
Why?
|
| Calcium Channel Blockers | 2 | 2000 | 165 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1985 | 0.070 |
Why?
|
| Superoxides | 3 | 1999 | 204 | 0.070 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 956 | 0.070 |
Why?
|
| Cell Count | 1 | 2008 | 320 | 0.070 |
Why?
|
| Oligopeptides | 2 | 2000 | 269 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 3 | 2006 | 1519 | 0.070 |
Why?
|
| Growth Hormone | 1 | 2008 | 92 | 0.070 |
Why?
|
| Comorbidity | 1 | 2013 | 1658 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 51 | 0.070 |
Why?
|
| Lisinopril | 1 | 2007 | 15 | 0.070 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 266 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2011 | 424 | 0.070 |
Why?
|
| Rats, Inbred Strains | 1 | 2007 | 321 | 0.070 |
Why?
|
| Sequence Alignment | 2 | 1999 | 366 | 0.070 |
Why?
|
| gamma-Glutamyltransferase | 3 | 2012 | 42 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2008 | 114 | 0.060 |
Why?
|
| Estradiol | 1 | 2011 | 533 | 0.060 |
Why?
|
| von Willebrand Factor | 1 | 2007 | 85 | 0.060 |
Why?
|
| Environment | 1 | 2009 | 305 | 0.060 |
Why?
|
| Sequence Analysis | 2 | 1997 | 35 | 0.060 |
Why?
|
| Adolescent | 6 | 2013 | 22428 | 0.060 |
Why?
|
| Cytoprotection | 2 | 2015 | 55 | 0.060 |
Why?
|
| Fibrinogen | 2 | 1999 | 177 | 0.060 |
Why?
|
| RNA, Catalytic | 1 | 2007 | 189 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2010 | 316 | 0.060 |
Why?
|
| Prednisone | 1 | 2007 | 221 | 0.060 |
Why?
|
| Colorado | 2 | 2016 | 4564 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2010 | 573 | 0.060 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 1997 | 51 | 0.060 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2006 | 38 | 0.060 |
Why?
|
| Genes, T-Cell Receptor alpha | 1 | 2005 | 11 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2001 | 1087 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2011 | 1486 | 0.060 |
Why?
|
| Energy Metabolism | 2 | 2024 | 935 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 467 | 0.060 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2005 | 49 | 0.060 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2005 | 5 | 0.060 |
Why?
|
| Caspase 7 | 1 | 2005 | 22 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3540 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 91 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2012 | 1306 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 60 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2010 | 790 | 0.050 |
Why?
|
| Tangier Disease | 1 | 1984 | 1 | 0.050 |
Why?
|
| Hypolipoproteinemias | 1 | 1984 | 2 | 0.050 |
Why?
|
| Case Management | 1 | 2005 | 67 | 0.050 |
Why?
|
| Thermosensing | 1 | 2004 | 12 | 0.050 |
Why?
|
| Microscopy, Electron | 3 | 1996 | 415 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 3409 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2008 | 770 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 158 | 0.050 |
Why?
|
| Vidarabine | 1 | 2004 | 32 | 0.050 |
Why?
|
| Microvilli | 1 | 2004 | 75 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2016 | 11787 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 250 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 14105 | 0.050 |
Why?
|
| Thoracic Surgery | 1 | 2006 | 144 | 0.050 |
Why?
|
| Hypertension, Renal | 2 | 2001 | 15 | 0.050 |
Why?
|
| Cytosol | 1 | 2004 | 227 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 262 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2004 | 168 | 0.050 |
Why?
|
| Nitrates | 2 | 2001 | 100 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2005 | 253 | 0.050 |
Why?
|
| Mycophenolic Acid | 1 | 2004 | 120 | 0.050 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 285 | 0.050 |
Why?
|
| LLC-PK1 Cells | 3 | 2015 | 18 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2006 | 498 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2011 | 914 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2007 | 535 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 5 | 2001 | 162 | 0.050 |
Why?
|
| Nitric Oxide Donors | 2 | 2001 | 20 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2004 | 191 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 278 | 0.050 |
Why?
|
| Leukocytes | 2 | 2001 | 295 | 0.050 |
Why?
|
| Cell Division | 1 | 2004 | 766 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 888 | 0.050 |
Why?
|
| Solubility | 2 | 2000 | 242 | 0.050 |
Why?
|
| Denervation | 1 | 2002 | 27 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 292 | 0.050 |
Why?
|
| Receptors, Virus | 2 | 2013 | 96 | 0.050 |
Why?
|
| Copper Sulfate | 1 | 2001 | 8 | 0.040 |
Why?
|
| Complement Pathway, Alternative | 1 | 2003 | 122 | 0.040 |
Why?
|
| Apolipoprotein B-100 | 1 | 2001 | 13 | 0.040 |
Why?
|
| Lipoxygenase | 1 | 2001 | 15 | 0.040 |
Why?
|
| Sepharose | 2 | 1999 | 32 | 0.040 |
Why?
|
| Biopsy | 1 | 2005 | 1075 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 86 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2005 | 358 | 0.040 |
Why?
|
| Receptors, Drug | 1 | 2001 | 10 | 0.040 |
Why?
|
| Reference Values | 3 | 1995 | 797 | 0.040 |
Why?
|
| Prevalence | 1 | 2008 | 2834 | 0.040 |
Why?
|
| Aldosterone | 1 | 2001 | 43 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2001 | 76 | 0.040 |
Why?
|
| Mucoproteins | 1 | 2001 | 8 | 0.040 |
Why?
|
| Liver | 1 | 2010 | 1887 | 0.040 |
Why?
|
| Aging | 1 | 2012 | 1966 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2021 | 20 | 0.040 |
Why?
|
| Spironolactone | 1 | 2001 | 39 | 0.040 |
Why?
|
| Temperature | 1 | 2004 | 679 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 1996 | 561 | 0.040 |
Why?
|
| Symporters | 1 | 2001 | 48 | 0.040 |
Why?
|
| Antihypertensive Agents | 2 | 2002 | 510 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 168 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 420 | 0.040 |
Why?
|
| Guanylate Cyclase | 1 | 2000 | 39 | 0.040 |
Why?
|
| Lung | 2 | 2011 | 4109 | 0.040 |
Why?
|
| Kinetics | 5 | 1999 | 1627 | 0.040 |
Why?
|
| Reoviridae Infections | 1 | 2001 | 55 | 0.040 |
Why?
|
| Detergents | 2 | 2000 | 44 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2000 | 181 | 0.040 |
Why?
|
| Octoxynol | 1 | 2000 | 13 | 0.040 |
Why?
|
| Insulin | 1 | 2011 | 2507 | 0.040 |
Why?
|
| Myocarditis | 1 | 2001 | 102 | 0.040 |
Why?
|
| Echocardiography | 2 | 2019 | 652 | 0.040 |
Why?
|
| Fibronectins | 2 | 1999 | 136 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 1999 | 88 | 0.040 |
Why?
|
| Sympathectomy | 1 | 2019 | 7 | 0.040 |
Why?
|
| Models, Biological | 4 | 2012 | 1821 | 0.040 |
Why?
|
| Infant | 4 | 2016 | 10034 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2019 | 223 | 0.040 |
Why?
|
| Choroid Neoplasms | 1 | 1998 | 9 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2013 | 5408 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1997 | 57 | 0.030 |
Why?
|
| Growth Substances | 1 | 1997 | 140 | 0.030 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 39 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 3863 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2017 | 5960 | 0.030 |
Why?
|
| Apolipoprotein L1 | 1 | 2017 | 14 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1997 | 85 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 1998 | 121 | 0.030 |
Why?
|
| Chromatography, Agarose | 1 | 1996 | 3 | 0.030 |
Why?
|
| Internationality | 1 | 2017 | 156 | 0.030 |
Why?
|
| Acidosis, Renal Tubular | 1 | 1996 | 4 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2016 | 112 | 0.030 |
Why?
|
| Cell Polarity | 1 | 1997 | 137 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 427 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1999 | 946 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 1996 | 101 | 0.030 |
Why?
|
| Cathepsin L | 1 | 1995 | 9 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 384 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1996 | 499 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
|
| Cell Adhesion | 3 | 2001 | 455 | 0.030 |
Why?
|
| Particle Size | 1 | 1996 | 411 | 0.030 |
Why?
|
| Visual Acuity | 1 | 1998 | 489 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 3 | 2001 | 49 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 574 | 0.030 |
Why?
|
| Cattle | 2 | 2011 | 1000 | 0.030 |
Why?
|
| Macrolides | 1 | 2014 | 69 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 476 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2012 | 851 | 0.030 |
Why?
|
| Lipopolysaccharides | 3 | 2002 | 863 | 0.030 |
Why?
|
| United States | 1 | 2011 | 15966 | 0.030 |
Why?
|
| Pancreas | 1 | 1996 | 341 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 940 | 0.030 |
Why?
|
| Myocardium | 1 | 2019 | 939 | 0.020 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2016 | 285 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2010 | 784 | 0.020 |
Why?
|
| Glomerular Mesangium | 1 | 1992 | 21 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 750 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1992 | 72 | 0.020 |
Why?
|
| Capillary Leak Syndrome | 1 | 2012 | 12 | 0.020 |
Why?
|
| Ion Transport | 1 | 2012 | 63 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 110 | 0.020 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2012 | 23 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 5868 | 0.020 |
Why?
|
| Gluconeogenesis | 1 | 2012 | 83 | 0.020 |
Why?
|
| North America | 1 | 2013 | 310 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2012 | 76 | 0.020 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2012 | 17 | 0.020 |
Why?
|
| New Zealand | 1 | 2012 | 54 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 327 | 0.020 |
Why?
|
| Health | 1 | 2012 | 81 | 0.020 |
Why?
|
| Genotype | 1 | 2017 | 1833 | 0.020 |
Why?
|
| Phosphates | 1 | 2012 | 180 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2016 | 6429 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1995 | 540 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2012 | 451 | 0.020 |
Why?
|
| Melanoma | 1 | 1998 | 761 | 0.020 |
Why?
|
| Heat-Shock Proteins | 2 | 2004 | 138 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 1025 | 0.020 |
Why?
|
| Models, Molecular | 1 | 1996 | 1618 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 614 | 0.020 |
Why?
|
| Cyclic GMP | 2 | 2001 | 92 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2011 | 62 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 529 | 0.020 |
Why?
|
| Molsidomine | 2 | 2001 | 5 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 854 | 0.020 |
Why?
|
| Glycolysis | 1 | 2012 | 339 | 0.020 |
Why?
|
| Candida | 1 | 2010 | 44 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 2947 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 547 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 630 | 0.020 |
Why?
|
| DNA Breaks | 1 | 2009 | 3 | 0.020 |
Why?
|
| DNA, Plant | 1 | 2009 | 16 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2145 | 0.020 |
Why?
|
| HIV Infections | 1 | 2004 | 3154 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2001 | 204 | 0.020 |
Why?
|
| Cell Shape | 1 | 2009 | 57 | 0.020 |
Why?
|
| Monocytes | 1 | 2011 | 538 | 0.020 |
Why?
|
| Plant Proteins | 1 | 2009 | 112 | 0.020 |
Why?
|
| Aminocaproic Acid | 2 | 1999 | 4 | 0.020 |
Why?
|
| Isoelectric Focusing | 2 | 1984 | 30 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 2117 | 0.020 |
Why?
|
| Hepatorenal Syndrome | 1 | 2007 | 15 | 0.020 |
Why?
|
| Collagen | 2 | 2001 | 456 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 383 | 0.020 |
Why?
|
| Regeneration | 1 | 2007 | 197 | 0.010 |
Why?
|
| Proteomics | 1 | 2012 | 1195 | 0.010 |
Why?
|
| Aneurysm, False | 1 | 2005 | 45 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 363 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2004 | 21 | 0.010 |
Why?
|
| Probability | 1 | 2006 | 310 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2006 | 309 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 1984 | 39 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 1985 | 370 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2004 | 26 | 0.010 |
Why?
|
| Autoradiography | 1 | 2004 | 64 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1984 | 331 | 0.010 |
Why?
|
| Osmotic Pressure | 1 | 2004 | 39 | 0.010 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2004 | 42 | 0.010 |
Why?
|
| Epitopes | 1 | 1985 | 485 | 0.010 |
Why?
|
| Complement C9 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2004 | 196 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 844 | 0.010 |
Why?
|
| Phentolamine | 1 | 2002 | 20 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 206 | 0.010 |
Why?
|
| Renin | 1 | 2002 | 34 | 0.010 |
Why?
|
| Complement Activation | 1 | 2006 | 411 | 0.010 |
Why?
|
| Ultraviolet Rays | 2 | 2004 | 388 | 0.010 |
Why?
|
| Complement C3 | 1 | 2003 | 191 | 0.010 |
Why?
|
| Triazenes | 1 | 2001 | 5 | 0.010 |
Why?
|
| Epinephrine | 1 | 2002 | 155 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2002 | 196 | 0.010 |
Why?
|
| Sodium Chloride Symporters | 1 | 2001 | 1 | 0.010 |
Why?
|
| Solute Carrier Family 12, Member 3 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Hydrolysis | 2 | 1999 | 199 | 0.010 |
Why?
|
| Liver Neoplasms | 2 | 1985 | 780 | 0.010 |
Why?
|
| Metabolism | 1 | 2001 | 44 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2001 | 81 | 0.010 |
Why?
|
| Uromodulin | 1 | 2001 | 22 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 2004 | 299 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2002 | 413 | 0.010 |
Why?
|
| Electrolytes | 1 | 2001 | 55 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2004 | 407 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2000 | 88 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2001 | 72 | 0.010 |
Why?
|
| Body Fluids | 1 | 2001 | 70 | 0.010 |
Why?
|
| Nitroprusside | 1 | 2000 | 72 | 0.010 |
Why?
|
| Gels | 1 | 2001 | 84 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 163 | 0.010 |
Why?
|
| Oligosaccharides | 1 | 2001 | 60 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1999 | 327 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 357 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 397 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2001 | 217 | 0.010 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 1999 | 31 | 0.010 |
Why?
|
| Opossums | 1 | 1999 | 9 | 0.010 |
Why?
|
| Lipids | 1 | 1984 | 710 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1999 | 40 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 1999 | 82 | 0.010 |
Why?
|
| Integrins | 1 | 1999 | 89 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 1999 | 156 | 0.010 |
Why?
|
| Solutions | 1 | 1999 | 166 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1999 | 158 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1999 | 141 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 1998 | 30 | 0.010 |
Why?
|
| Sodium | 1 | 1999 | 197 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1999 | 131 | 0.010 |
Why?
|
| Benzoates | 1 | 1998 | 50 | 0.010 |
Why?
|
| Pupil | 1 | 1998 | 22 | 0.010 |
Why?
|
| Indocyanine Green | 1 | 1998 | 42 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2001 | 555 | 0.010 |
Why?
|
| Fluorescein Angiography | 1 | 1998 | 189 | 0.010 |
Why?
|
| Polymers | 1 | 2001 | 499 | 0.010 |
Why?
|
| Imidazoles | 1 | 1998 | 254 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1995 | 17066 | 0.010 |
Why?
|
| Plasminogen | 1 | 1996 | 27 | 0.010 |
Why?
|
| Palmitic Acids | 1 | 1996 | 10 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 193 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 1996 | 25 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1998 | 329 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1996 | 104 | 0.010 |
Why?
|
| Palmitic Acid | 1 | 1996 | 42 | 0.010 |
Why?
|
| Chemical Fractionation | 1 | 1995 | 28 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1995 | 53 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 81 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1996 | 93 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1996 | 191 | 0.010 |
Why?
|
| Potassium | 1 | 1996 | 152 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2000 | 780 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1995 | 299 | 0.010 |
Why?
|
| Protease Inhibitors | 2 | 1985 | 102 | 0.010 |
Why?
|
| Arginine | 1 | 1996 | 262 | 0.010 |
Why?
|
| Binding Sites | 1 | 1996 | 1329 | 0.010 |
Why?
|
| Protein Binding | 1 | 1996 | 2273 | 0.000 |
Why?
|
| Urea | 1 | 1969 | 84 | 0.000 |
Why?
|
| Lipoproteins | 1 | 1969 | 169 | 0.000 |
Why?
|
| Blood Proteins | 1 | 1969 | 249 | 0.000 |
Why?
|
| Apolipoprotein A-II | 1 | 1985 | 5 | 0.000 |
Why?
|
| Culture Media | 1 | 1984 | 161 | 0.000 |
Why?
|
| Peptides | 1 | 1969 | 995 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1985 | 893 | 0.000 |
Why?
|
| Freeze Etching | 1 | 1977 | 1 | 0.000 |
Why?
|
| Phospholipases | 1 | 1977 | 14 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1977 | 199 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1977 | 151 | 0.000 |
Why?
|
| Electrophoresis, Disc | 1 | 1969 | 3 | 0.000 |
Why?
|
| Immunodiffusion | 1 | 1969 | 12 | 0.000 |
Why?
|
| Methods | 1 | 1969 | 69 | 0.000 |
Why?
|
| Chemistry | 1 | 1969 | 41 | 0.000 |
Why?
|
| Immune Sera | 1 | 1969 | 77 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1969 | 81 | 0.000 |
Why?
|
| Blood Group Antigens | 1 | 1969 | 15 | 0.000 |
Why?
|
| Ultracentrifugation | 1 | 1969 | 51 | 0.000 |
Why?
|
| Spectrophotometry | 1 | 1969 | 61 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1969 | 131 | 0.000 |
Why?
|
| Spectrum Analysis | 1 | 1969 | 93 | 0.000 |
Why?
|
| Dextrans | 1 | 1969 | 86 | 0.000 |
Why?
|
| Rabbits | 1 | 1969 | 648 | 0.000 |
Why?
|
| Antigens | 1 | 1969 | 347 | 0.000 |
Why?
|
| Amino Acids | 1 | 1969 | 521 | 0.000 |
Why?
|